Abbott Laboratories Beheer
Beheer criteriumcontroles 3/4
De CEO Abbott Laboratories is Robert Ford, benoemd in Oct2018, heeft een ambtstermijn van 6.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 23.27M, bestaande uit 6.4% salaris en 93.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.024% van de aandelen van het bedrijf, ter waarde $ 48.95M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 5.8 jaar.
Belangrijke informatie
Robert Ford
Algemeen directeur
US$23.3m
Totale compensatie
| Percentage CEO-salaris | 6.4% |
| Dienstverband CEO | 6.1yrs |
| Eigendom CEO | 0.02% |
| Management gemiddelde ambtstermijn | 5.5yrs |
| Gemiddelde ambtstermijn bestuur | 5.8yrs |
Recente managementupdates
Recent updates
Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31
Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11A Look At The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Aug 16Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13These 4 Measures Indicate That Abbott Laboratories (NYSE:ABT) Is Using Debt Reasonably Well
Jul 01Abbott Laboratories (NYSE:ABT) Is Doing The Right Things To Multiply Its Share Price
Jun 18Investors Still Waiting For A Pull Back In Abbott Laboratories (NYSE:ABT)
Jun 04Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18Abbott Laboratories: Organic Growth Will Be Key To Q1 Earnings
Apr 17Estimating The Intrinsic Value Of Abbott Laboratories (NYSE:ABT)
Apr 15Abbott Laboratories: Buy This World-Class Dividend Growth Stock Now
Mar 21Abbott Laboratories (NYSE:ABT) Might Have The Makings Of A Multi-Bagger
Mar 19Here's Why Abbott Laboratories (NYSE:ABT) Can Manage Its Debt Responsibly
Mar 06Abbott Labs' Reversal Is Here - CGM Tailwinds In 2024
Feb 27Abbott Laboratories' (NYSE:ABT) Shares May Have Run Too Fast Too Soon
Feb 08The King Is Back: Abbott Laboratories' Path To >11% Annual Returns
Jan 29The Abbott Laboratories (NYSE:ABT) Full-Year Results Are Out And Analysts Have Published New Forecasts
Jan 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$6b |
| Jun 30 2024 | n/a | n/a | US$6b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$8b |
| Jun 30 2022 | n/a | n/a | US$9b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$25m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$20m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$12m | US$1m | US$4b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$3b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$8m | US$784k | US$2b |
| Sep 30 2018 | n/a | n/a | US$802m |
| Jun 30 2018 | n/a | n/a | US$812m |
| Mar 31 2018 | n/a | n/a | US$365m |
| Dec 31 2017 | US$5m | US$675k | US$344m |
Compensatie versus markt: De totale vergoeding ($USD 23.27M ) Robert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.67M ).
Compensatie versus inkomsten: De vergoeding van Robert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Robert Ford (50 yo)
6.1yrs
Tenure
US$23,268,171
Compensatie
Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 6.1yrs | US$23.27m | 0.024% $ 49.0m | |
| CFO & Executive VP of Finance | 1.2yrs | US$3.32m | 0.0023% $ 4.6m | |
| Executive VP | 11.8yrs | US$7.42m | 0.011% $ 21.7m | |
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 10.2yrs | US$5.93m | 0.0073% $ 14.7m | |
| Executive VP & Group President of Medical Devices | 5.8yrs | US$5.50m | 0.0035% $ 7.2m | |
| Senior VP of Business & Technology Services and Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Vice President of Investor Relations. | no data | geen gegevens | geen gegevens | |
| VP and Chief Ethics & Compliance Officer | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Commercial Operations | 1.8yrs | geen gegevens | geen gegevens | |
| Executive Vice President of Human Resources | 5.3yrs | geen gegevens | 0.0059% $ 12.0m | |
| Senior Vice President of Global Marketing & External Affairs | no data | geen gegevens | geen gegevens | |
| Executive Vice President of Diabetes Care | 9.4yrs | geen gegevens | 0.0042% $ 8.4m |
5.5yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ABT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Board | 5yrs | US$23.27m | 0.024% $ 49.0m | |
| Independent Director | 7.8yrs | US$349.29k | 0.39% $ 786.8m | |
| Independent Director | 7.8yrs | US$341.96k | 0.00020% $ 406.8k | |
| Lead Independent Director | 12.9yrs | US$405.96k | 0.00027% $ 549.1k | |
| Independent Director | 3.6yrs | US$337.96k | 0% $ 0 | |
| Independent Director | 16.1yrs | US$441.44k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$283.96k | 0% $ 0 | |
| Independent Director | 6.4yrs | US$331.96k | 0.00018% $ 366.1k | |
| Independent Director | 12.9yrs | US$362.60k | 0.00015% $ 305.1k | |
| Independent Director | 2.2yrs | US$354.96k | 0% $ 0 | |
| Independent Director | 5.2yrs | US$331.19k | 0% $ 0 | |
| Independent Director | 3.3yrs | US$356.96k | 0% $ 0 |
5.8yrs
Gemiddelde duur
62yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ABT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).